Otitis Media – Pipeline Review, H2 2012

Otitis Media – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Otitis Media - Pipeline Review, H2 2012', provides an overview of the Otitis Media therapeutic pipeline. This report provides information on the therapeutic development for Otitis Media, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Otitis Media. 'Otitis Media - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Otitis Media.
- A review of the Otitis Media products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Otitis Media pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Otitis Media.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Otitis Media pipeline depth and focus of Otitis Media therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Otitis Media Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Otitis Media 7
Otitis Media Therapeutics under Development by Companies 9
Otitis Media Therapeutics under Investigation by Universities/Institutes 10
Late Stage Products 11
Comparative Analysis 11
Mid Clinical Stage Products 12
Comparative Analysis 12
Pre-Clinical Stage Products 13
Comparative Analysis 13
Otitis Media Therapeutics – Products under Development by Companies 14
Otitis Media Therapeutics – Products under Investigation by Universities/Institutes 15
Companies Involved in Otitis Media Therapeutics Development 16
OctoPlus N.V. 16
Otonomy, Inc. 17
Laboratorios SALVAT S.A. 18
Otitis Media – Therapeutics Assessment 19
Assessment by Monotherapy Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
DPK-060 - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
OP-145 - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
OTO-201 - Drug Profile 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
Xylitol Syrup - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PNCRM9 Vaccine - Drug Profile 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
Juzen-Taiho-To - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
Cetraxal - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
Drug For Ear Disorders - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
Otitis Media Therapeutics – Drug Profile Updates 33
Otitis Media Therapeutics - Dormant Products 34
Otitis Media – Product Development Milestones 35
Featured News & Press Releases 35
Apr 18, 2012: MerLion Initiates Phase III Clinical Program To Evaluate Finafloxacin For Treatment Of Acute Otitis Media 35
Jan 16, 2012: Pergamum Initiates Phase II Trial With DPK-060 In Outer Ear Infections 35
Jun 08, 2011: Otonomy Announces Positive Preclinical Results For OTO-201 36
Jan 08, 2010: LG Life Sciences Receives Approval For Additional Indication Of Factive For Otitis Media 37
Jul 28, 2009: Wyeth recalls lot of Prevnar vaccine. 37
Jul 28, 2008: OctoPlus Proves Efficacy Of OP-145 In Phase II Ear Infection Study 37
Oct 04, 2007: Wyeth Comments on PREVNAR and Trends in Pneumococcal Disease. 38
Jul 27, 2007: Wyeth Team Recognized by White House With Prestigious National Medal of Technology for PREVNAR Vaccine. 39
Nov 22, 2006: OctoPlus Grants Green Cross Corporation Exclusive Korean License To OP-145 39
Jul 05, 2006: Octoplus Obtains Full Rights To OP-145 For The Treatment Of Chronic Middle Ear Infection And Other Indications 40
Appendix 41
Methodology 41
Coverage 41
Secondary Research 41
Primary Research 41
Expert Panel Validation 41
Contact Us 42
Disclaimer 42

List of Tables
Number of Products Under Development for Otitis Media, H2 2012 7
Products under Development for Otitis Media – Comparative Analysis, H2 2012 8
Number of Products under Development by Companies, H2 2012 9
Number of Products under Investigation by Universities/Institutes, H2 2012 10
Comparative Analysis by Late Stage Development, H2 2012 11
Comparative Analysis by Mid Clinical Stage Development, H2 2012 12
Comparative Analysis by Pre-Clinical Stage Development, H2 2012 13
Products under Development by Companies, H2 2012 14
Products under Investigation by Universities/Institutes, H2 2012 15
OctoPlus N.V., H2 2012 16
Otonomy, Inc., H2 2012 17
Laboratorios SALVAT S.A., H2 2012 18
Assessment by Monotherapy Products, H2 2012 19
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Stage and Molecule Type, H2 2012 23
Otitis Media Therapeutics – Drug Profile Updates 33
Otitis Media Therapeutics – Dormant Products 34

List of Figures
Number of Products under Development for Otitis Media, H2 2012 7
Products under Development for Otitis Media – Comparative Analysis, H2 2012 8
Products under Development by Companies, H2 2012 9
Products under Investigation by Universities/Institutes, H2 2012 10
Late Stage Products, H2 2012 11
Mid Clinical Stage Products, H2 2012 12
Pre-Clinical Stage Products, H2 2012 13
Assessment by Monotherapy Products, H2 2012 19
Assessment by Route of Administration, H2 2012 20
Assessment by Stage and Route of Administration, H2 2012 21
Assessment by Molecule Type, H2 2012 22
Assessment by Stage and Molecule Type, H2 2012 23